Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of a Goal-directed Hemodynamic Therapy Driven by ECOM on Morbidity and Mortality After Cardiac Surgery? (ECOMIII)

16 de abril de 2013 actualizado por: University Hospital, Caen

Does Goal-directed Hemodynamic Therapy Driven by Endotracheal Cardiac Output Monitoring System During Surgical Intervention Reduce Hospital Stay and Major Adverse Cardiac Events Following Cardiac Surgery?

Goal-directed hemodynamic and fluid optimizations are shown to be a key factor of the medical care during anesthesia.According to medical literature, goal-directed fluid and hemodynamic optimizations are more efficient when based on the dynamic parameters than when based on the statics ones, and the major dynamic criteria is the cardiac output. Unfortunately, transpulmonary thermodilution, the device considered as "The gold standard" to evaluate cardiac output is associated with many complications.Furthermore, devices commercialized in the past decade were not able to replace the transpulmonary thermodilution.

As all monitoring devices aren't reliable enough to be widely used in practice they are left aside in benefits of the clinical evaluation. Even though, hemodynamic optimization based on the analysis of several clinical parameters seems to guarantee good cares thanks to a favorable benefits/risks balance, it could be improved by new plug and play mini-invasive systems.

In the investigators opinion, the ECOM system seems able to provide a monitoring tool which responds to all the expectations of a modern hemodynamic monitoring device. It uses a well known technique, the bioimpedance. The investigators suppose this device should be more efficient than the one that has been used before. Indeed, as the system is build on the endotracheal tube, it comes closer to the aorta, where all the measures are made, and the recorded signal should be less affected by the passage through the surrounding tissues.

This randomized and controlled trial will study Patients scheduled for elective coronary surgery with cardiopulmonary bypass.

The purpose of this trial is to evaluate the benefits of an intraoperative goal-directed hemodynamic therapy based on the ECOM cardiac output measure on mortality and major postoperative cardiac morbidity after coronary surgery, when compared with a standard management strategy.

Patients will be allocated into control and ECOM groups, of 50 peoples each. The standard management strategy, applied to the control group, will be set and led by the attending anesthetist, based on the analysis of further clinical parameters. The ECOM Group will face the hemodynamic optimization strategy led by the ECOM evaluation of cardiac output and stroke volume variation.

The main hypothesis is that the hemodynamic strategy led by the ECOM cardiac output measure will reduce mortality and morbidity after cardiac surgery.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

100

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Calvados
      • Caen, Calvados, Francia, 14000
        • University Hospital of Caen

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

16 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Any man or woman
  • Over 18 year-old
  • After obtaining written informed consent
  • Scheduled for elective coronary surgery with CPB

Exclusion Criteria:

  • Emergency surgery (< 24h)
  • Combined cardiac surgery
  • Patients < 18 years-old and/or unable to give informed consent
  • Patients who refuse to give informed consent
  • Pregnancy
  • PVC allergy

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: ECOM group
50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass

goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) & cardiac index (CI).

goals:

  • SVV < 11%
  • IC > 2,2 ml/min/m²

During the anesthesia

Otros nombres:
  • Endotracheal cardiac output monitoring
Comparador activo: standard management group
50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass

goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index

  • Diuresis > 0,5ml/kg/h
  • Blood pressure , PAM > 65 mmHg
  • Pulse pressure variation
  • CVP 8 to 12 cmH20
  • Visual aspect of the heart
  • Overload signs During the anesthesia

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
length of hospital stay
Periodo de tiempo: Data collected at the exit of hospital or at death, if during hospital stay.patients will be followed for the duration of hospital stay, an expected average of 10 days. expected before 1 month
Data collected at the exit of hospital or at death, if during hospital stay.patients will be followed for the duration of hospital stay, an expected average of 10 days. expected before 1 month

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Number of major adverse cardiac events during stay in hospital
Periodo de tiempo: Data collected at the exit of ICU, at the exit of hospital or at death if during hospital stay.patients will be followed for the duration of hospital stay, an expected average of 10 days.Up to 1 month
Data collected at the exit of ICU, at the exit of hospital or at death if during hospital stay.patients will be followed for the duration of hospital stay, an expected average of 10 days.Up to 1 month
Length of stay in ICU
Periodo de tiempo: at the exit of ICU or at death, if during hospital stay.expected before 1 month
at the exit of ICU or at death, if during hospital stay.expected before 1 month
In-hospital mortality
Periodo de tiempo: at the end of the study. up to 12 month
at the end of the study. up to 12 month
Number of patients with Major adverse cardiac events during in-hospital stay.
Periodo de tiempo: at the end of the study. Up to 12 month
at the end of the study. Up to 12 month

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Director de estudio: Jean-Luc Fellahi, EA3212: groupe coeur et ischémie

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de febrero de 2012

Finalización primaria (Actual)

1 de febrero de 2013

Finalización del estudio (Actual)

1 de febrero de 2013

Fechas de registro del estudio

Enviado por primera vez

7 de febrero de 2012

Primero enviado que cumplió con los criterios de control de calidad

17 de febrero de 2012

Publicado por primera vez (Estimar)

20 de febrero de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

17 de abril de 2013

Última actualización enviada que cumplió con los criterios de control de calidad

16 de abril de 2013

Última verificación

1 de abril de 2013

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2011-A01210-41

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir